Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Stoke Therapeutics announced two presentations of data for STK-002, an investigational medicine targeting Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The company also provided an update on its Phase 1 OSPREY study, with initial safety and efficacy data an
Stoke Therapeutics announced that data for its investigational medicine STK-002, intended for the treatment of Autosomal Dominant Optic Atrophy (ADOA), will be presented at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting.